Limits...
Ability of PITX2 methylation to predict survival in patients with prostate cancer.

Li JZ, Zhang Y, Wen B, Li M, Wang YJ - Onco Targets Ther (2015)

Bottom Line: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels.The methylation possibility of each of the candidate genes were maximized.Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China ; Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China.

ABSTRACT

Background: The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer.

Methods: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score ≤7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer.

Results: The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

Conclusion: Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score.

No MeSH data available.


Related in: MedlinePlus

Methylation level of each gene in benign prostatic hyperplasia (white color) and prostatic cancer (gray color).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The circles represent the statistical differences between the prostatic hyperplasia and prostatic cancer.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664542&req=5

f2-ott-8-3507: Methylation level of each gene in benign prostatic hyperplasia (white color) and prostatic cancer (gray color).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The circles represent the statistical differences between the prostatic hyperplasia and prostatic cancer.

Mentions: Gene methylation levels for EPB41L3, SPARC, PITX2, WNT5a, and TPM4 were tested in 135 patients (Figure 2), and the number of genes detected in each patient differed. Table 1 shows the case number and the number of patients included in the analysis of each gene. Table 1 shows that each gene methylation with a kind of layered distribution in case group and control group. The mean duration of follow-up was 7.8 years (median was 6.1 years) in the case group, and 15.3 years (interquartile range 6.8) in the control group. The methylation of each gene, univariate conditional logistic regression analysis of death from prostate cancer, and odds ratio (OD) are illustrated in Table 1. Before multiple testing adjustment, the methylation level of PITX2 and WNT5a was evaluated to determine which of the two genes may be related to a patient’s death due to prostate cancer (OD 1.56, 95% confidence interval 1.17–2.08 vs OD 1.28, 95% confidence interval 1.02–1.60). After adjusting for a 5% false positive rate, the methylation level of only PITX2 remained significant for predicting the risk of death from prostate cancer (P=0.005). Since the methylation level of PITX2 increased by 10%, the prostate cancer-related death events will increase by at least 1.56 times.


Ability of PITX2 methylation to predict survival in patients with prostate cancer.

Li JZ, Zhang Y, Wen B, Li M, Wang YJ - Onco Targets Ther (2015)

Methylation level of each gene in benign prostatic hyperplasia (white color) and prostatic cancer (gray color).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The circles represent the statistical differences between the prostatic hyperplasia and prostatic cancer.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664542&req=5

f2-ott-8-3507: Methylation level of each gene in benign prostatic hyperplasia (white color) and prostatic cancer (gray color).Notes: Each position of value boxplot represents the 5th, 25th, 50th, 75th, and 95th percentiles. The circles represent the statistical differences between the prostatic hyperplasia and prostatic cancer.
Mentions: Gene methylation levels for EPB41L3, SPARC, PITX2, WNT5a, and TPM4 were tested in 135 patients (Figure 2), and the number of genes detected in each patient differed. Table 1 shows the case number and the number of patients included in the analysis of each gene. Table 1 shows that each gene methylation with a kind of layered distribution in case group and control group. The mean duration of follow-up was 7.8 years (median was 6.1 years) in the case group, and 15.3 years (interquartile range 6.8) in the control group. The methylation of each gene, univariate conditional logistic regression analysis of death from prostate cancer, and odds ratio (OD) are illustrated in Table 1. Before multiple testing adjustment, the methylation level of PITX2 and WNT5a was evaluated to determine which of the two genes may be related to a patient’s death due to prostate cancer (OD 1.56, 95% confidence interval 1.17–2.08 vs OD 1.28, 95% confidence interval 1.02–1.60). After adjusting for a 5% false positive rate, the methylation level of only PITX2 remained significant for predicting the risk of death from prostate cancer (P=0.005). Since the methylation level of PITX2 increased by 10%, the prostate cancer-related death events will increase by at least 1.56 times.

Bottom Line: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels.The methylation possibility of each of the candidate genes were maximized.Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, People's Republic of China ; Department of Urology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China.

ABSTRACT

Background: The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer.

Methods: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1:2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score ≤7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer.

Results: The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.

Conclusion: Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score.

No MeSH data available.


Related in: MedlinePlus